MANUFACTURING

HOME OPERATIONS MANUFACTURING

CHIKALTHANA, AURANGABAD

 Set up Year : 1979

 Products Manufactured :Liquid & Capsule
 Area :2,718 Sq.M. ( Built up )
This facility has fabulous quality systems, processes and documentation procedures. In-house developed
software records and ensures strict compliances of laid down procedures at every stage of manufacturing.

PAITHAN , AURANGABAD

 Set up Year : 1983

 Products Manufactured :Tablet, Capsules & Dry Powder
 Area :28,099 Sq.M. ( Built up )
This facility is among the few pharmaceutical formulation facilities in the country that has approvals
from the most stringent authorities in the world like USFDA and WHO Prequalification.
 CHITEGAON , AURANGABAD

 Set up Year :2009

 Products Manufactured :Tablets, Capsules, Powder & Jelly
 Area :4,900 Sq.M. ( Built up )
This facility is dedicated to meet the requirements of Emerging Markets, equipped with suitable
machines for each section, this facility also keeps sharp eye on environment protection.

API WALUJ , AURANGABAD

 Set up Year : 2009

 Dedicated for :Active Pharma Ingredient (Raw Material)
 Area :3,197 Sq.M. ( Built up )
This facility is Ajanta's only Active Pharmaceutical Ingredient (API) (also known as bulk drug, used as
raw material for our formulation plants) facility committed mainly for captive consumption.
 DAHEJ, GUJARAT

 Set up Year : 2014

 Products Manufactured :Tablets, Capsules, Powder & Jelly
 Area :41,713 Sq.M. ( Built up )
The facility has been specially constructed for catering to the requirements of markets like USA, WHO
and Emerging Markets. The facility has been approved by world’s most stringent authority US FDA
without any observation in April 2017. It has capacity to manufacture annually about 1,740 Million
Tablets, 216 Million Capsules and 150 Million Powder sachets. Facility has been built complying
international standards.

GUWAHATI, ASSAM

 Set up Year : 2017

 Products Manufactured :Tablets, Ointments & Jelly
 Area :53,000 Sq.M. ( Built up )
In early 2016 APL had acquired a plot of land in Kokjhar, District Kamrup (R), Guwahati, Assam.
Company has successfully operationalized Phase 1 of the facility on 22nd January 2017 for Tablets &
Jelly, which was built in record time of 12 months. This facility has been planned keeping in view the
growth for another 5 years in Domestic Market.
 MAURITIUS, GOODLANDS

 Set up Year : 1996

 Products Manufactured :Tablets & Capsules.
 Area :27,000 Sq.ft. ( Built up )
Complying with WHO cGMP guidelines, this facility follows all the quality parameters followed by
Ajanta Pharma in India and has excellent quality control section to ensure best international quality for
its products. Ministry of Health delegations from several countries have inspected, audited and approved
this manufacturing facility.
HOME OPERATIONS RESEARCH & DEVELOPMENT

1
Ajanta Pharma views Research and Development as a vital component of Business Strategy that will
provide us with an competitive advantage. We recognize that 'innovation is the key to success' and have
been consistently investing in R&D over the last decade.

2
Company's R&D facility has 850+ diligent and committed scientists. Based in Mumbai, the facility
has a range of state-of-the-art equipment for formulation development, working on different dosage
forms such as topical creams, ophthalmological preparations, nasal sprays, solid orals, liquids and dry
powder inhalers. We have an equally well equipped Active Pharmaceutical Ingredient (API) lab at
this R&D Centre to synthesize high value APIs for some of our key products. Many of the
formulations developed by our R&D are first of their kind and now hold leading positions in their sub-
therapeutic segments across different geographies.

3
The research centre primarily focuses on development of new formulations with an objective to introduce
first-to-market products providing Convenience And Better Patient Compliance. We have been taking
continuous initiatives towards technology absorption, adaptation and innovation at our R&D Centre,
resulting in the upgrade of all equipment to encompass latest technological developments in the field of
research.

4
Few of our notable R&D achievements are in the segment of anti-malarial with our flagship brand, Artefan
- the first generic product to have been pre-qualified by the World Health Organization (WHO),
Geneva. Our other key brands include Kamagra (Sildenafil Citrate) & Apcalis-SX(Tadalafil), both used
in the treatment of Male Erectile Dysfunction. These are available in the conventional tablet as well as in
an innovative "jelly" form which is the world's first of its kind dosage form for this molecule.

5
Our team is provided with an environment that nurtures excellence and innovation which is most essential
to develop complex and challenging first-time combination products and also first-to-launch generic
products in our focus therapeutic segments. The R&D team is completely involved in all projects from
concept to Phase IV study tracking market acceptability and after-launch status.

6
Our R&D hub is fully equipped with modern amenities and technology for accessing reference
material, environmental monitoring, data collection & analysis, record keeping and archiving.
Ajanta Pharma is a specialty pharmaceutical company engaged in development,
manufacturing and marketing of quality finished dosages. Committed to 'Serve Health
Care Needs Worldwide', we produce a comprehensive range of specialty products
targeting different therapeutic segments for treatment of patients, customised to each
market we are present in. We clearly understand our customer’s needs and use cutting
edge technology to present innovative solutions. Our business includes Branded
Generics in emerging markets of Asia and Africa, Generics in the developed markets of
USA and Institution sales.

The branded generics business is spread in India and more than 30 emerging countries
across Africa, CIS, the Middle East and South East Asia. In India we have presence in
high growth specialty segments of cardiology, dermatology, ophthalmology and pain
management where we have been able to provide consistently innovative products,
many being 1st to the market, for patient convenience and compliance.

Emerging markets are the major contributors in our branded generic business where we
are present across Asia and Africa. We have designed customised basket of
products for each of these markets and serve wide range of therapeutic segments like
Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric,
Respiratory & General Health products.

We are gradually building a meaningful presence in the US market with select product
portfolio, which include complex technology products to get the competitive advantage in
the market place. We expect US market to be our key growth driver in the coming
years.

Company’s Institutional business comprises of supplies to various government bodies in

India and supply of Anti-Malarial products under WHO approved programs in Africa.

Ajanta operates 7 state-of-the-artmanufacturing facilities in India and Mauritius. 2 of

the facilities in India have been successfully approved by US FDA. We are further
expanding our manufacturing capabilities to meet our growth requirement in future.

We employ over 6,500+ people worldwide and our products are sold in over 30
countries. Ajanta’s team members are driven to fulfill its mission; a commitment to
‘Serving Global Healthcare needs with Empathy, Innovation & Technology’.
Years Milestone

1973 - Ajanta started with re-packing of generic products

- Launched branded OTC (Over The Counter) products

1979 - 1stManufacturing Facility set up in India – (Chikalthana)

1986 - Started production at 2nd manufacturing facility in India – (Paithan)

1989 - Launched block buster OTC product '30+' in India

1992 - Foray in international market

1995 - Established subsidiary in Mauritius with manufacturing facility

- Got listed on National Stock Exchange (NSE) and Bombay Stock Exchange
2000 (BSE)

- Strategic shift from OTC to Innovative Specialised Prescription Products in

2005 Ophthal, Dermatology & Cardiology

2007 - Set-up dedicated fully equipped R&D facility in Mumbai

- Bought a manufacturing facility at Chitegaon to fuel company's growth

- API facility set up in Waluj for captive consumption
- 1st Generic Company in the world to get WHO Geneva Pre-qualification for
2009 Anti-Malarial Drug

- Entered Philippines market with unique product portfolio through Ajanta

2010 Pharma Philippines Inc.

- Emerged as a strong speciality player in domestic market in Ophthalmology,

Dermatology and Cardiology with many brands holding leadership
2011 positions

2012 - Ranked among the Top 10 Pharma companies in Franco Africa

2013 - Began Sales in the USA

- Income growth of 30% and profit growth of 62% CAGR over last 5 years
- 2nd Dedicated R&D centre Set up in Kandivli for India and Emerging Markets
2014 - Inaugurated a New Facility in Dahej, Bharuch, Gujarat, India

- Inaugurated & commissioned 1st phase at a New Facility in Guwahati,

Assam, India
2017 - Dahej facility receives successful US FDA approval.

2018 - Commissioned Ajanta's 1st ever Derma facility in Guwahati

 Mission
Our mission is to Serve Global Healthcare needs through Empathy, Innovation and Technology. We
believe that to ensure sustained growth, we need to clearly understand our customer's needs and use cutting
edge technology to present innovative solutions.

Philosophy
At Ajanta, we believe in the art of first creating opportunities and then optimizing them to the fullest. In
this manner, we identify the unmet medical needs across therapies in different markets and capitalize on
them to optimum levels ahead of competition.

Branded Generics Business

At Ajanta, we produce a comprehensive range of specialty products targeting different therapeutic
segments for treatment of patients, customised to each market we are present in. We clearly understand our
customer's needs and use cutting edge technology to present innovative solutions.

We identify complex areas that need innovation and commit ourselves to find a solution, within a defined
time frame. We extend this thought-process to the markets we choose to enter and the capabilities we want
to build. The branded generics business is spread in India and more than 30 emerging countries across
Africa, CIS, the Middle East and South East Asia.

India is at the heart of Ajanta's growth plans, with huge potential in the specialty segments. We have
presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain
management where we have been able to provide consistently innovative products, many being 1st to the
market, for patient convenience and compliance. This has enabled us to take leadership in many sub
therapeutic segments we are present in. We continue to innovate and build a robust product pipeline for
our future growth.

Emerging markets are the major contributors in our branded generic business where we are present across
Asia and Africa. We chose each of the market where we are present in and designed a customised basket
of products for each of these markets. We serve wide range of therapeutic segments like Anti-Biotic, Anti-
Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health
products.
Ajanta has been doing pioneering efforts in having ground presence through its own field force in the
emerging markets and aggressively promoting brands to take leadership positions. We clearly have an edge
in the market place with our product and promotion strategy which enabled us to be ranked 4th largest
pharma company in Franco Africa as per IMS. We have also successfully carved an important position in
the Philippines market in a very short period of time.

With the objective of building sustainable and scalable business model, we have been continuously filing
products for registration in different countries of emerging markets, across therapeutic segments. This will
ensure sustained growth for the company in years to come.

Generics Business
As a part of our philosophy to build sustainable and scalable business model, Ajanta Pharma set its eye on
entering the world's largest and most stringent pharmaceutical market - USA. We carved out select product
portfolio, which include complex technology products to get the competitive advantage in the market
place. We have also made substantial investments in our R&D facilities and thereby acquired required
technical and regulatory expertise to penetrate the market.
In our quest for expansion in the regulated markets, we expect US market to be our key growth driver in
the coming years. With an objective of building a critical size in the marketplace, many important
programs are on the cards like investments in R&D, Manufacturing, Team, etc. Our products are already
available on the shelf in US through our subsidiary, located in New Jersey, the hub of pharma industry in
USA.

Currently we have 20 final approved products by US Food and Drug Administration (FDA), which are
either commercialized or in process of being commercialized. Additional 4 ANDAs is tentatively
approved, and other 15 ANDAs are under review with the US FDA (as on 31st May 2018). We are further
planning to file about 10-12 ANDA's every year.

Institutional Business
Company's Institutional business comprises of India Business and Africa Business. In India, company is a
reliable supplier for various government bodies like Armed forces, government hospitals, canteens, stores
department, etc. The product basket for India market includes multivitamins, antibiotics, eye drops, cough
syrups, etc.

In Africa, Ajanta Pharma was the 1st Generic Company to obtain 'WHO Pre-Qualification' for Anti-
Malarial product, a combination of Artemether + Lumefantrine. Company has been innovating on this
product since then and has given many new variations for patient convenience and compliance. Currently,
company is one of the 6 major players to supply Anti-Malarial product to Global Fund.